Loading candles…
Shilpa Medicare, established in 1987 and headquartered in Raichur, Karnataka, operates in the pharmaceutical industry. The company manufactures niche active pharmaceutical ingredients (APIs), intermediates, and formulations. Its product portfolio includes 16 injectable dosage forms and 19 oral solid dosage forms marketed under Shilpa Medicare Limited (SML), along with 13 formulations developed by its wholly owned subsidiary, Shilpa Therapeutics. The business segments encompass APIs, intermediates, formulations, contract research and manufacturing services, oncology, non-oncology, biologics, and emerging specialty areas such as Antibody Drug Conjugates (ADCs). Shilpa Medicare has evolved into a specialist drug delivery entity with a diversified presence in these segments. The company maintains a significant regulatory presence across more than 50 countries, including the United States, the European Union, and various emerging markets.
This page is a live market overview for SHILPA MEDICARE LTD (SHILPAMED) on the NSE. As a listed security, SHILPA MEDICARE LTD is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for SHILPAMED before placing trades on tick2trade.
As of the latest feed, SHILPAMED last traded at ₹759.75 on NSE, up ₹20.95 (2.84%) from the previous close of ₹738.8. Today's session range is ₹731.45 – ₹773.75, against a 52-week band of ₹259.5 – ₹773.75. Traded volume today stands at 63.04L shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for SHILPAMED in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether SHILPAMED is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for SHILPA MEDICARE LTD before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in SHILPAMED. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated SHILPAMED option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Unaudited Results - FY26 | To consider and approve the Unaudited financial results for the period ended Jun 30, 2026 | 5 Aug 2026 |
| Audited Results - Q4 & FY26 | To consider and approve the Audited Standalone and Consolidated Financial Results for the fourth quarter and year ended on March 31, 2026, along with Audit R… | 22 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 6 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 13 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 13 Aug 2025 |
| Bonus | To consider bonus | 13 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 | 26 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.